NEO NeoGenomics
- 13.710
- -0.290-2.07%
- 13.910
- +0.200+1.46%
NeoGenomics News
Form 144 | NeoGenomics(NEO.US) Officer Proposes to Sell 198.34K in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $NeoGenomics(NEO.US)$ Officer BRUCE K CROWTHER intends to sell 13,882 shares of its common stock on May 28, with a total market value of approximately $198.34K. Sour
NeoGenomics Introduces Comprehensive Lung Solution & Feature Hematopathology Services At ASCO
NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Cli
NeoGenomics to Introduce Comprehensive Lung Solution & Feature Hematopathology Services at ASCO, Offering Actionable Insights to Support Treatment Management
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will showcase its versatile lung solution and its COMPASS Hematopathology Services portfolio at the American Society of Clinical Oncology (ASCO) conference in Chicago, May 31–June 4 (booth #31093).
NeoGenomics(NEO.US) Officer Sells US$16,511.26 in Common Stock
$NeoGenomics(NEO.US)$ Officer Olivo Alicia C sold 1,049 shares of common stock on May 15, 2024 at an average price of $15.74 for a total value of $16,511.26.Source: Announcement What is statement of c
Increasing Losses Over Three Years Doesn't Faze NeoGenomics (NASDAQ:NEO) Investors as Stock Rises 5.3% This Past Week
If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough on longer term NeoGenomics, Inc. (NASDAQ:NEO) shareholders. Unfortunately, they
NeoGenomics Earnings Analysis: Q1 Recap
The Q1 earnings report for NeoGenomics (NASDAQ:NEO) was released on Tuesday, April 30, 2024 at 07:30 AM.Here's what investors need to know about the latest announcement.EarningsNeoGenomics beat estima
Piper Sandler Gives a Buy Rating to NeoGenomics (NEO)
NeoGenomics Is Maintained at Buy by BTIG
NeoGenomics Is Maintained at Buy by BTIG
BTIG Maintains Buy on NeoGenomics, Lowers Price Target to $21
BTIG analyst Mark Massaro maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $23 to $21.
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO) and Envista Holdings (NVST)
Buy Rating Affirmed for NeoGenomics Amid Strong Q1 Performance and Growth Prospects
NeoGenomics Is Maintained at Buy by TD Cowen
NeoGenomics Is Maintained at Buy by TD Cowen
TD Cowen Maintains Buy on NeoGenomics, Lowers Price Target to $20
TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and lowers the price target from $21 to $20.
NeoGenomics Coverage Assumed by Craig-Hallum at Buy
NeoGenomics Coverage Assumed by Craig-Hallum at Buy
Craig-Hallum Assumes NeoGenomics at Buy, Announces Price Target of $26
Craig-Hallum analyst Alex Nowark assumes NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $26.
Benchmark: Reiterates NeoGenomics (NEO.US) rating, adjusted from buy to buy rating, target price $18.00.
Benchmark: Reiterates NeoGenomics (NEO.US) rating, adjusted from buy to buy rating, target price $18.00.
Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
Benchmark analyst Bruce Jackson reiterates NeoGenomics (NASDAQ:NEO) with a Buy and maintains $18 price target.
NeoGenomics Inc (NEO) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ...
Earnings Call Summary | NeoGenomics(NEO.US) Q1 2024 Earnings Conference
The following is a summary of the NeoGenomics, Inc. (NEO) Q1 2024 Earnings Call Transcript:Financial Performance:NeoGenomics reported Q1 revenue of $156 million, marking a 14% growth compared to the p
Where NeoGenomics Stands With Analysts
Ratings for NeoGenomics (NASDAQ:NEO) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary of their recen
Analysis
Price Target
No Data
